Abstract: Oxysterol-statin compounds and methods of synthesizing the same are provided for use in promoting osteogenesis, osteoinduction and/or osteoconduction. Methods of synthesizing in a single container OXY133-statin compounds having high yields and improved process safety are also provided. Methods for synthesizing OXY133-statin compounds that are stereoselective are also provided.

Abstract: Embodiments include a system including a sealed prefilled drug-reservoir. The drug-reservoir may include a unit dosage of treprostinil in a sterile fluid composition. The composition may not include an antimicrobial preservative. The treprostinil may be present at a dosage of between 0.1 mg/mL and 25 mg/mL. In addition, the treprostinil may be treprostinil sodium Furthermore, the composition may include sodium chloride. The composition may also include a sodium ion from sodium chloride in a concentration from 3000 to 4500 ppm. The composition may not include metacresol.

Abstract: This invention includes fusogenic compounds, and compositions and methods of use thereof. The fusogenic compounds can be used for making nanoparticle compositions for use in biopharmaceuticals and therapeutics. More particularly, this invention relates to compounds, compositions and methods for providing nanoparticles to incorporate or encapsulate active agents, to deliver and distribute the active agents to cells, tissues, organs, and subjects.

Abstract: The present invention relates to a novel process for converting the unwanted S enantiomer form to its useful raceme with respect to a 4-aminoindane derivative and to novel intermediates of said process.

Abstract: A method for producing methyldichlorophosphane, the method including: allowing methane and phosphorus trichloride to react in the presence of an additive using a metal compound, or a metal compound carried on a carrier, or both thereof.

Abstract: A method for producing an N-vinylcarboxylic acid amide is provided, the method focusing on unsaturated aldehydes that are contained as impurities generated during a reaction. The method for producing an N-vinylcarboxylic acid amide includes a step for controlling the contained amount of unsaturated aldehydes in the N-vinylcarboxylic acid amide to be not more than 20 mass ppm.

Abstract: This invention provides compounds of Formulae (IA), (IB), (IC), (ID), (IE), (IF), (IG), (IH), (IJ), (IK), (IL), (II), (III), (IIIA), and (IIIB); pharmaceutically acceptable salts and solvates thereof; and compositions thereof.

Abstract: A 4-(p-trifluoromethylbenzyl)-3-fluoro-1,2,4-triphenylamine derivative, a pharmaceutical composition and applications thereof are disclosed. The general chemical formula of the derivative is shown in formula I, where, R is a C1-C6 alkyl group, a cycloalkyl group, a heteroatom-containing cycloalkyl group, an aryl group or a heteroatom-containing aryl group, the heteroatom is selected from N or O, and the n is 0, 1, 2 or 3. The pharmaceutical composition contains any one of the above-mentioned 4-(p-trifluoromethylbenzyl)-3-fluoro-1,2,4-triphenylamine derivatives as an active ingredient, and one or more pharmaceutically acceptable carriers. The derivative and the pharmaceutical composition activate KCNQ channel currents. Thus, the derivative can be applied to prepare a KCNQ potassium channel opener, and can be used as the active ingredients of an antiepileptic pharmaceutical preparation, an antianxiety pharmaceutical preparation and a neuropathic pain-relieving pharmaceutical preparation.

Abstract: Novel compounds that find use as imaging agents within nuclear medicine applications (PET imaging) for imaging of cardiac innervation are disclosed. These PET based radiotracers may exhibit increased stability, decreased NE release thereby reducing side effects, improved quantitative data, and/or high affinity for VMAT over prior radiotracers. In some instances the compounds are developed by derivatizing certain compounds with 18F in a variety of positions: aryl, alkyl, a keto, benzylic, beta-alkylethers, gamma-propylalkylethers and beta-proplylalkylethers. Alternatively or additionally, a methyl group a is added to the amine, and/or the catechol functionality is either eliminated or masked as a way of making these compounds more stable.

Abstract: A catalyst for catalytic oxidation of furfural to prepare maleic acid, relating to the technical field of renewable energy. The catalyst is a mixture of a bromide and a base. A method for preparing the catalyst in catalytic oxidation of furfural to prepare maleic acid. The method includes: mixing the furfural, the bromide-base, an oxidant and a solvent to carry out a reaction to obtain the maleic acid. The present invention has the advantages that the method has a relatively high conversion rate of furfural and a relatively high yield of maleic acid, the conversion rate of furfural is up to 99%, the yield of maleic acid is up to 68.04%; and the catalyst has a high catalytic selectivity and reusability.

Abstract: The present disclosure provides novel compounds capable of functioning as Myocyte Enhancer Factor 2 (MEF2) modulators, as well as compositions, pharmaceutical formulations, methods of synthesis and kits.

Abstract: A method for producing tricyclo[5.2.1.02,6]decane-2-carboxylate according to the present invention is a method for producing tricyclo[5.2.1.02,6]decane-2-carboxylate, containing reacting tricyclo[5.2.1.02,6]deca-3-ene in a dilute solution containing the tricyclo[5.2.1.02,6]deca-3-ene with carbon monoxide in the presence of an acid catalyst, followed by reaction with an alcohol, wherein the dilute solution contains 100 parts by mass or more of a tricyclo[5.2.1.02,6]decane isomer mixture based on 100 parts by mass of the tricyclo[5.2.1.02,6]deca-3-ene, the tricyclo[5.2.1.02,6]decane isomer mixture contains endo-tricyclo[5.2.1.02,6]decane (Endo form of TCD) and exo-tricyclo[5.2.1.02,6]decane (Exo form of TCD), and a constituent ratio thereof (Endo form of TCD/Exo form of TCD) is greater than 1.0.

Abstract: Systems and methods of recovering 2-ethyl hexanol from crude alcohol are disclosed. The crude alcohol originates from a reactor that produces 2-ethyl hexanol and is first distilled in a first distillation column The distillate from the first distillation column is then further distilled in a second distillation column. A side stream is drawn from the second distillation column and recycled to the reactor that produces 2-ethyl hexanol. The bottom stream from the second distillation column is mixed with the bottom stream from the first distillation column. The combined stream is further distilled in a third distillation column to produce a 2-ethyl hexanol product stream.

Abstract: A novel compound has pharmacological activities comparable to those of Nahlsgen and is storable excellently stably. The compound can be produced by a method according to the present invention for producing an optically active 2-amino-phosphonoalkanoic acid salt. In the method, a starting material DL-2-amino-phosphonoalkanoic acid represented by Formula (1) or a hydrate thereof is reacted with an optically active basic compound other than an optically active lysine, to give a diastereomeric salt mixture including a first salt (including a hydrate salt) between a D-2-amino-phosphonoalkanoic acid represented by Formula (1-1) and the optically active basic compound, and a second salt (including a hydrate salt) between an L-2-amino-phosphonoalkanoic acid represented by Formula (1-2) and the optically active basic compound. The diastereomeric salt mixture is fractionally crystallized to isolate one of the first and second diastereomeric salts.

Abstract: The present invention relates to N-(7-fluoro-1,1,3-trimethyl-1H-inden-4yl) amides and a process for preparing same. The novel amides are useful in a process for converting the unwanted S enantiomer form of a 4-aminoindane derivative to its useful raceme.

Abstract: Disclosed are preparation of zinc linolenate, and application thereof in preparing an anti-Helicobacter pylori drug. Zinc chloride is dissolved in sterile water, and the zinc chloride solution is heated and activated in a reactor kettle, and then naturally cooled to room temperature; 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride, N-hydroxysulfosuccinimide sodium salt and linolenic acid are dissolved in an EMS solvent and activated in nitrogen gas; the activated zinc chloride and the activated linolenic acid are heated and reacted, then left for standing after the reaction is finished; a dialysis bag is used to perform dialysis in pure water until the pure water is clear and transparent; and a vacuum freeze dryer is used to perform drying, and zinc linolenate is obtained. The present invention successfully prepares zinc linolenate, with high yield, and the zinc linolenate has a good Helicobacter pylori inhibiting effect.

Abstract: Disclosed is a chemical process of preparing dehydrohedione from Hedione via ?-chlorination and elimination steps. The process can be conducted in a one-pot process or in a continuous reactor system. Accordingly, a simple and cost effective process of preparing cis-Hedione enriched products is developed through reduction of dehydrohedione in the presence of a chiral catalyst system.

Abstract: Provided is a method for producing a high-purity, high-quality semicarbazide compound at a high yield by a simple method. The semicarbazide compound is recrystallized by a solvent containing a halogenated hydrocarbon. Dichloromethane is preferred as the halogenated hydrocarbon.

Abstract: The present invention relates to a method for preparing substituted 4-aminoindane derivatives of the general formula (I) by rearrangement of compounds of the formula (II) in HF, wherein R1, R2, R3, R4, and R5 have the definitions as specified in the description.

Abstract: A compound of the formula (I) ALK—SO2—O—O—SO2OX, wherein ALK is a branched or unbranched alkyl group, especially a methyl, ethyl, propyl, butyl, isopropyl, isobutyl group, or a higher alkyl group, and X=hydrogen, zinc, Aluminium, an alkali or alkaline earth metal.